Health Experts Say Funding Delays Threaten Immunisation

Nigeria's immunisation programme faces a critical juncture. Health experts are sounding alarms over recurring delays in fund releases that directly undermine vaccine availability and service delivery across Africa's most populous nation. For European investors monitoring opportunities in African healthcare, this dysfunction represents both a cautionary tale and a market signal worth decoding.

The underlying problem is straightforward but systemic: Nigeria's federal and state governments struggle to disburse allocated funds for immunisation programmes on schedule. These delays cascade through the entire supply chain—from procurement of vaccines to cold chain maintenance to final-mile distribution in rural clinics. When funds dry up unpredictably, health workers cannot stock vaccines, clinics run dry, and vaccination coverage drops. The gains painstakingly built over years of international donor support evaporate within months.

For context, Nigeria has made genuine progress on immunisation. Childhood vaccination rates have climbed toward 70% in recent years, supported heavily by GAVI (the Vaccine Alliance) and bilateral donors. But this progress is fragile. Without sustained, predictable funding, the country risks backsliding into the epidemiological vulnerabilities of the 2010s—a period when vaccine-preventable diseases like measles and polio posed serious public health threats.

The immediate cause of these delays appears to be broader fiscal instability. Nigeria's federal budget faces competing pressures: servicing a growing debt burden, managing oil price volatility, and funding ambitious infrastructure projects. Health budgets are often treated as discretionary rather than essential, making them vulnerable to reprioritisation mid-fiscal year. This reflects a deeper governance challenge: weak institutional capacity for multi-year budget planning and weak political incentives to ring-fence health spending.

**What this means for European investors:**

First, it signals that the Nigerian healthcare market—while large and growing—requires patient capital and operational sophistication. European pharmaceutical companies or healthcare service providers looking to establish distribution networks or manufacturing hubs in Nigeria cannot rely on government procurement predictability alone. Successful operators will need to diversify revenue streams (private sector, NGO partnerships, corporate health schemes) or negotiate advance purchase agreements with donor organisations.

Second, it highlights an opportunity for innovative financing mechanisms. European impact investors and development finance institutions (DFIs) could deploy blended finance structures—combining concessional capital with commercial returns—to de-risk vaccine supply chains. Companies offering cold chain solutions, logistics optimisation, or last-mile distribution in Nigeria operate in a market starved of capital but facing genuine demand.

Third, it underscores why European health-tech and diagnostics companies should view Africa's institutional weaknesses as addressable problems, not immovable obstacles. The countries with the strongest healthcare outcomes in sub-Saharan Africa (Rwanda, Botswana, South Africa) haven't eliminated fiscal challenges—they've designed systems resilient to them. Nigeria's failure to do so is a policy choice, not an iron law.

The broader lesson: African healthcare markets are growing, but success requires understanding local political economy. European investors who treat Nigeria's public health system as a solved problem—or as unsolvable—will miss opportunities. Those who map the dysfunction, identify pressure points, and build business models around them will find genuine returns and impact.

---

#